AQR Capital Management LLC lowered its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 61.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 20,024 shares of the biopharmaceutical company’s stock after selling 32,539 shares during the quarter. AQR Capital Management LLC’s holdings in Dynavax Technologies were worth $248,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in Dynavax Technologies by 184.6% in the 2nd quarter. Millennium Management LLC now owns 129,902 shares of the biopharmaceutical company’s stock worth $1,981,000 after buying an additional 84,254 shares during the period. Northern Trust Corp raised its position in shares of Dynavax Technologies by 9.8% in the 2nd quarter. Northern Trust Corp now owns 750,442 shares of the biopharmaceutical company’s stock worth $11,445,000 after acquiring an additional 66,677 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Dynavax Technologies in the 3rd quarter worth approximately $1,292,000. Franklin Resources Inc. raised its position in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Franklin Resources Inc. now owns 3,136,406 shares of the biopharmaceutical company’s stock worth $38,891,000 after acquiring an additional 239,876 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Dynavax Technologies by 5.2% in the 2nd quarter. BlackRock Inc. now owns 4,067,094 shares of the biopharmaceutical company’s stock worth $62,023,000 after acquiring an additional 202,306 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

DVAX stock opened at $10.95 on Friday. Dynavax Technologies Co. has a twelve month low of $7.85 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.29 and a quick ratio of 5.90. The company has a market cap of $686.47 million, a P/E ratio of -6.33 and a beta of 0.69.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative net margin of 5,044.85% and a negative return on equity of 97.79%. The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $3.16 million. During the same period last year, the business earned ($0.38) EPS. The firm’s quarterly revenue was up 2822.0% on a year-over-year basis. Equities research analysts forecast that Dynavax Technologies Co. will post -2.51 earnings per share for the current fiscal year.

DVAX has been the subject of several research reports. BidaskClub raised Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 11th. Cantor Fitzgerald set a $30.00 target price on Dynavax Technologies and gave the stock a “buy” rating in a research report on Friday, October 19th. Royal Bank of Canada increased their target price on Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a research report on Monday, October 22nd. Cowen reissued a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, October 22nd. Finally, ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $28.00.

WARNING: “Dynavax Technologies Co. (DVAX) Shares Sold by AQR Capital Management LLC” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/dynavax-technologies-co-dvax-shares-sold-by-aqr-capital-management-llc/2789411.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Recommended Story: Treasury Bonds

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.